Efficacy News and Research

RSS

A retrospective surveillance study of Pfizer–BioNTech BNT162b2 mRNA COVID-19 vaccination in Israel

One recent study provided nationwide estimates of the burden of SARS-CoV-2 that could be averted by Israel's vaccination campaign.

28 Sep 2021

NIAID awards approximately $36.3 million to fuel vaccine research for coronaviruses

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has awarded approximately $36.3 million to three academic institutions to conduct research to develop vaccines to protect against multiple types of coronaviruses and viral variants.

28 Sep 2021

Classic antidepressants show potential to enhance modern cancer treatments

Classic antidepressants could help improve modern cancer treatments. They slowed the growth of pancreatic and colon cancers in mice, and when combined with immunotherapy, they even stopped the cancer growth long-term.

28 Sep 2021

Novel polyclonal antibody therapy meets the criteria for graduation to phase 3 in ACTIV-2 trial

The AIDS Clinical Trials Group (ACTG), the largest global HIV research network, which recently expanded its focus to include evaluating outpatient treatment for COVID-19, today announced that SAB-185, a novel polyclonal antibody therapy, has demonstrated safety and efficacy in phase 2 that meet the criteria for graduation to phase 3 in the ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies Trial (ACTG A5401).

28 Sep 2021

Scientists identify potential antibody candidate with broad-spectrum neutralizing efficacy against SARS-CoV-2 variants

A team of scientists from China and the USA has recently described the antiviral efficacy of a monoclonal antibody candidate targeting the spike receptor-binding domain (RBD) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Importantly, they have observed that emerging spike mutations could not affect the potency of this antibody. The study is currently available on the bioRxiv* preprint server.

27 Sep 2021

Pfizer-BioNTech’s COVID-19 vaccine appears effective against SARS-CoV-2 mu variant

Researchers in Japan have conducted a study showing that the vaccine developed by Pfizer-BioNTech to protect against coronavirus disease 2019 (COVID-19) seems to be adequately effective against the B.1.621 (mu) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

27 Sep 2021

Third COVID-19 mRNA vaccine booster dose indicated for myelofibrosis patients

A new study discusses the utility of a third booster dose in patients with myelofibrosis.

27 Sep 2021

Monoclonal antibodies may reduce hospital stay, but not mortality in COVID-19

A new study explores the real-world efficacy of monoclonal antibodies against COVID-19 in averting severe disease.

27 Sep 2021

Chronic COVID-19 and divergent variants of SARS-CoV-2

A new study discusses the isolation of two variants of concern (VOCs) from an immunocompromised COVID-19 patient.

27 Sep 2021

A new SARS-CoV-2 variant (B.1.1.523) capable of escaping immune protections

A new study describes a new variant that possesses a novel combination of various concerning mutations at the spike region.

27 Sep 2021

Hyperbranched polylysine nanopolymer as potential broad-spectrum antiviral against SARS-CoV-2

The findings from this study suggest that HPNs may inhibit viral replication and budding.

27 Sep 2021

Characterization of SARS-CoV-2 infections diagnosed after mRNA BNT162b2 vaccination

A team from the National Institute for Infectious Diseases “L. Spallanzani” (INMI) has recently reported their study on 94 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections (47.9% symptomatic, 52.1% asymptomatic) that occurred after the first or second vaccine dose against SARS-CoV-2 in the Lazio region (Central Italy).

27 Sep 2021

SARS-CoV-2 entry inhibitors show antiviral activity

A new study used a combination of a computer-aided drug design approach and cell-based in vitro assays to identify five potential SARS-CoV-2 inhibitors.

27 Sep 2021

Design of peptide vaccine for SARS-CoV-2

In a recent study, researchers from the US identified two immunogenic non-structural proteins - PLpro and RdRp - from immunodominant gene regions ORF1ab, ORF3a and ORF9b as potential targets for a vaccine against SARS-CoV-2.

27 Sep 2021

Study suggests two doses of COVID-19 vaccine may offer some protection for kidney transplant patients

Researchers from Toronto, Canada, performed a cohort study to analyze the impact of COVID-19 vaccination on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and clinical outcomes in kidney transplant patients. This study is available on the preprint server, medRxiv.

27 Sep 2021

COVID-19 vaccine effectiveness barely affected by Delta variant, research suggests

Has the Delta (B.1.617.2) variant reduced vaccine effectiveness? If you ask Ian Foster of Argonne National Laboratory and colleagues, the answer is not really. New research published in the preprint medRxiv* server suggests vaccines approved in the United States are stable and well-performing.

27 Sep 2021

Study shows SARS-CoV-2 breakthrough infections 18-fold lower than rate of infections among unvaccinated

In a recent study, researchers conducted a pilot study to assess the prevalence and features of VBTs through the use of sequencing and case data.

26 Sep 2021

Vaccine hesitancy and vaccination passports – a Japanese study

A new study from Keio University, Japan, provides an evaluation of the effectiveness of relaxing public interactions following vaccination against COVID-19.

26 Sep 2021

Novel antibody candidate shows potent binding to diverse SARS-CoV-2 variant mutations

Twist Bioscience Corporation (Nasdaq: TWST) today reported that its internally-discovered antibody candidate TB202-3 (CoVIC-094), demonstrated potent binding to diverse SARS-CoV-2 variant mutations, including strains with the E484K, N501Y, D614G, Y453F and K417N mutations in pseudovirus assays, indicating this therapeutic antibody may be effective in treating many strains of COVID-19.

25 Sep 2021

Researchers describe a novel role for hnRNP E1 protein in binding DNA in the nucleus

Cancer is a devastating disease and is the second leading cause of death in the U.S. One of the hallmarks of cancer is genomic instability, or the tendency to accumulate mutations and damage to the DNA that leads to genome alterations during cell division.

25 Sep 2021

Efficacy News and Research

A retrospective surveillance study of Pfizer–BioNTech BNT162b2 mRNA COVID-19 vaccination in Israel

NIAID awards approximately $36.3 million to fuel vaccine research for coronaviruses

Classic antidepressants show potential to enhance modern cancer treatments

Novel polyclonal antibody therapy meets the criteria for graduation to phase 3 in ACTIV-2 trial

Scientists identify potential antibody candidate with broad-spectrum neutralizing efficacy against SARS-CoV-2 variants

Pfizer-BioNTech’s COVID-19 vaccine appears effective against SARS-CoV-2 mu variant

Third COVID-19 mRNA vaccine booster dose indicated for myelofibrosis patients

Monoclonal antibodies may reduce hospital stay, but not mortality in COVID-19

Chronic COVID-19 and divergent variants of SARS-CoV-2

A new SARS-CoV-2 variant (B.1.1.523) capable of escaping immune protections

Hyperbranched polylysine nanopolymer as potential broad-spectrum antiviral against SARS-CoV-2

Characterization of SARS-CoV-2 infections diagnosed after mRNA BNT162b2 vaccination

SARS-CoV-2 entry inhibitors show antiviral activity

Design of peptide vaccine for SARS-CoV-2

Study suggests two doses of COVID-19 vaccine may offer some protection for kidney transplant patients

COVID-19 vaccine effectiveness barely affected by Delta variant, research suggests

Study shows SARS-CoV-2 breakthrough infections 18-fold lower than rate of infections among unvaccinated

Vaccine hesitancy and vaccination passports – a Japanese study

Novel antibody candidate shows potent binding to diverse SARS-CoV-2 variant mutations

Researchers describe a novel role for hnRNP E1 protein in binding DNA in the nucleus

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News